quinoxalines has been researched along with Infections, Respiratory in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, C; Gandhi, N; Grant, NN; Halmos, B; Kim, C; Krochmal, R; Liu, SV; Reuss, JE; Sackstein, P; Yeung, V | 1 |
| Alami, NN; Asatryan, A; Burroughs, M; Fredrick, LM; Heo, J; Hou, J; Jia, J; Kalluri, HV; Kim, YJ; Krishnan, P; Lim, SG; Liu, W; Lu, W; Mobashery, N; Tripathi, R; Wang, G; Wei, L; Xie, Q; Xie, W; Zhang, M | 1 |
| De Gandt, JB | 1 |
1 trial(s) available for quinoxalines and Infections, Respiratory
| Article | Year |
|---|---|
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Asia; Benzimidazoles; Case-Control Studies; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Prevalence; Proline; Pyrrolidines; Quinoxalines; Respiratory Tract Infections; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
2 other study(ies) available for quinoxalines and Infections, Respiratory
| Article | Year |
|---|---|
Use of Erdafitinib in
Topics: Humans; Papillomavirus Infections; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Respiratory Tract Infections | 2022 |
[Guanamycin in the ambulatory antibiotic treatment of ENT diseases].
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Humans; Otitis Media; Otorhinolaryngologic Diseases; Pharyngeal Diseases; Quinoxalines; Respiratory Tract Infections; Sinusitis | 1975 |